OTC : AQSZF

Aequus Pharmaceuticals Inc.

$0.0026 USD

$0 (0.0%)

Volume
22K
Average Volume
40.77K
Market Capitalization
$344.85K
P/E Ratio
-1.52
Dividend Yield
0.00%
Price Target
Year High
$0.01
Year Low
$0.00
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$0.03
Company Overview

OTC

Douglas Glen Janzen

Drug Manufacturers - Specialty & Generic

Healthcare

AQSZF

12

CA

USD

https://www.aequuspharma.ca

+1 236 330 7084

007636103

N/A

Liquidity Metrics

-0.87

0.03

0.03

0.00

0.00

Sales & Valuation

$584.24K

0.95

-0.10

-43.73

0.00

Profitability

-$0.0164

-$2.18M

-62.96%

-62.96%

6.18%

-223.56%

P/E Metrics

-1.52

-0.01

-0.01

Analyst Price Target & Rating

Strong Sell

1/5

0 Analysts

%

Poll Results

About Aequus Pharmaceuticals Inc. (OTC:AQSZF) Stock

Aequus Pharmaceuticals Inc. is a specialized pharmaceutical firm based in Vancouver, Canada, dedicated to the development and commercialization of medicinal products across the country. The company concentrates its efforts on several key medical disciplines, including neurological conditions, ophthalmology, and transplantation medicine. Its current commercial portfolio features: Vistitan, an ophthalmic solution designed to lower elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Tacrolimus IR, an immunosuppressive drug prescribed for the management and prevention of acute organ rejection subsequent to transplantation procedures. The Evolve range of dry eye products, formulated to alleviate various symptoms associated with dry eye disease ... and blepharitis, such as discomfort, stinging, burning, and dryness. Additional preservative-free ophthalmic products. In its development pipeline, Aequus is advancing: Extended-release oral tablet formulations of Topiramate XR and Oxcarbazepine XR, both intended for the treatment of epilepsy. AQS1303, a transdermal patch containing pyridoxine/doxylamine, aimed at addressing nausea and vomiting during pregnancy. AQS1304, a cannabinoid-based therapeutic under investigation for neurological disorders. Aequus Pharmaceuticals has forged strategic alliances with other industry players, including Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for the marketing of extended-release anti-epileptic medications; and Medicom Healthcare Ltd., with whom they collaborate on preservative-free treatments within ophthalmology. The company was established in 2013.

Frequently Asked Questions

What is the current Aequus Pharmaceuticals Inc. (AQSZF) stock price?

Aequus Pharmaceuticals Inc.(OTC:AQSZF) stock price is $0.0026 in the last trading session. During the trading session, AQSZF stock reached the peak price of $0.008 while $0.0002 was the lowest point it dropped to. The percentage change in AQSZF stock occurred in the recent session was 0.0% while the dollar amount for the price change in AQSZF stock was $0.

AQSZF's industry and sector of operation?

The OTC listed AQSZF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of AQSZF?

Douglas Glen Janzen | Chairman, Chief Executive Officer & President
|
|
|
|

How many employees does AQSZF have?

Number of AQSZF employees currently stands at 12. AQSZF operates from 200 Granville Street, Vancouver, BC V6C 1S4, CA.

Link for AQSZF official website?

Official Website of AQSZF is: https://www.aequuspharma.ca

How do I contact AQSZF?

AQSZF could be contacted at phone #+1 236 330 7084 and can also be accessed through its website. AQSZF operates from 200 Granville Street, Vancouver, BC V6C 1S4, CA.

How many shares of AQSZF are traded daily?

The average number of AQSZF shares traded daily for last 3 months was 40.77K.

What is the market cap of AQSZF currently?

The market value of AQSZF currently stands at $344.85K with its latest stock price at $0.0026